Analysts believe Impax Laboratories, Inc. (NASDAQ:IPXL) is worth $18.53 per share

Impax Laboratories, Inc. (NASDAQ:IPXL) registered a 4.56% increase, still its new closing price is 18.03% up from the company’s 1 year high of 38.43.It posted 10.44% gains in previous 5 sessions and is now the subject of 10 analysts who together assign a hold rating on stock. 1 of Wall Street analysts have an underperform rating; the 1 sells versus 2 buy or better ratings. The 16 stock analysts following this company have an average price target at $18.53, with individual PT in the $12.00-$48.00 range. The shares moved at $13.75, implying that brokerage firms see shares losing about -62.56% in twelve months time.

Impax Laboratories, Inc. (IPXL) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 3.77% rise year to date. A Director at Impax Laboratories, Inc. (IPXL) offloaded shares in a transaction closed on Monday August 15, 2016. BENET LESLIE Z sold 10,092 shares in the company at $22.81 each and collected $230,000 in proceeds. BENET LESLIE Z now owns 30,733 shares in the company after this transaction. A SVP and General Counsel in the company, SCHLOSSBERG MARK A, disclosed a transaction on Friday September 11, 2015 that ended up generating $322,001 from the sale of 7,457 shares at $43.3 per share.

Impax Laboratories, Inc. (NASDAQ:IPXL) Upcoming Results on Tap

Impax Laboratories, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $0.33 in that period. Sales during the quarter are predicted to arrive at $224.72 million.

Earnings surprise history: Last quarter, the company posted approximately $227.91 million in revenue and EPS of $0.37. The mean forecast was for $234.76 million and $0.38 a share, respectively. One quarter earlier, revenue for the stock was at $172.59 million, with earnings at $0.21/share.

Impax Laboratories, Inc. (IPXL) Brokerage Update 

Impax Laboratories, Inc. (IPXL) is in WallachBeth’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by WallachBeth, according to news reported on Monday November 14, 2016.Another important research note was issued by BofA/Merrill on Monday November 07, 2016.The firm downgraded IPXL to Underperform from Neutral. Over the last six months and over the last three months, the shares of Impax Laboratories, Inc. (IPXL), have changed -55.60% and -31.59%, respectively.